LT3662910T - Trail geno indukcijai skirtas farmakoforas - Google Patents

Trail geno indukcijai skirtas farmakoforas

Info

Publication number: LT3662910T
Authority: LT; Lithuania
Prior art keywords: pharmacophore; gene induction; trail gene; trail; induction
Prior art date: 2014-03-31

Application number

LTEP19218049.5T

Other languages

English (en)

Inventor

Kim D Janda

Nicholas T. JACOB

Jonathan W. LOCKNER

Original Assignee

The Scripps Research Institute

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-03-31

Filing date

2015-03-30

Publication date

2024-12-27

2015-03-30 Application filed by The Scripps Research Institute filed Critical The Scripps Research Institute

2024-12-27 Publication of LT3662910T publication Critical patent/LT3662910T/lt

Links

230000006698 induction Effects 0.000 title 1
108090000623 proteins and genes Proteins 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Hematology (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

LTEP19218049.5T 2014-03-31 2015-03-30 Trail geno indukcijai skirtas farmakoforas LT3662910T (lt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201461972689P	2014-03-31	2014-03-31

Publications (1)

Publication Number	Publication Date
LT3662910T true LT3662910T (lt)	2024-12-27

Family

ID=54241169

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
LTEP15772254.7T LT3125898T (lt)	2014-03-31	2015-03-30	Farmakoforas, skirtas trail indukcijai
LTEP19218049.5T LT3662910T (lt)	2014-03-31	2015-03-30	Trail geno indukcijai skirtas farmakoforas

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
LTEP15772254.7T LT3125898T (lt)	2014-03-31	2015-03-30	Farmakoforas, skirtas trail indukcijai

Country Status (20)

Country	Link
US (5)	US10239877B2 (lt)
EP (3)	EP3125898B1 (lt)
JP (4)	JP6756435B2 (lt)
KR (2)	KR102611067B1 (lt)
CN (2)	CN106456643B (lt)
AU (4)	AU2015241069B2 (lt)
CA (2)	CA2944452C (lt)
CY (1)	CY1123093T1 (lt)
DK (2)	DK3662910T3 (lt)
ES (2)	ES2999685T3 (lt)
FI (1)	FI3662910T3 (lt)
HR (2)	HRP20241680T1 (lt)
HU (2)	HUE069651T2 (lt)
LT (2)	LT3125898T (lt)
PL (2)	PL3125898T3 (lt)
PT (2)	PT3125898T (lt)
RS (2)	RS66254B1 (lt)
SI (2)	SI3662910T1 (lt)
SM (2)	SMT202000219T1 (lt)
WO (1)	WO2015153468A1 (lt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9688679B2 (en)	2013-03-13	2017-06-27	Oncoceutics, Inc.	7-benzyl-4-(methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-A]pyrido[3,4-E]pyrimidin-5 (1H)-one, salts thereof and methods of using the same in combination therapy
SI2968294T1 (sl)	2013-03-13	2019-08-30	Oncoceutics, Inc.	7-benzil-10-(2-metilbenzil)-2,6,7,8,9,10-heksahidroimidazo(1,2-A)pirido (4,3-D)pirimidin-5(3H)-on za uporabo pri zdravljenju raka
US9376437B2 (en)	2013-03-13	2016-06-28	Oncoceutics, Inc	7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy
KR102318238B1 (ko) *	2013-11-15	2021-10-26	온코슈틱스 인코포레이티드	7-벤질-4-(2-메틸벤질)-2,4,6,7,8,9-헥사하이드로이미다조[1,2-a]피리도[3,4-e]피리미딘-5(1H)-온, 이의 염 및 이의 용도
JP6756435B2 (ja)	2014-03-31	2020-09-16	ザスクリプスリサーチインスティテュート	Ｔｒａｉｌ誘導のためのファーマコフォア
HUE052821T2 (hu) *	2015-01-30	2021-05-28	Oncoceutics Inc	7-benzil-4-(4-trifluormetil)benzil-1,2,6,7,8,9-hexahidroimidazo[1,2-a]pirido[3,4-e]pirimidin-5(4H)-on és sói és azok terápiában történõ alkalmazása
CN104860948B (zh) *	2015-05-15	2017-09-26	南京盖特医药技术有限公司	咪唑并嘧啶酮类化合物及其制备方法和应用
RS66519B1 (sr) *	2016-01-29	2025-03-31	Oncoceutics Inc	Modulacija g protein-spregnutog receptora (gpcr) pomoću imipridona
CA3033667A1 (en)	2016-08-12	2018-02-15	Nanjing Gator Meditech Company, Ltd.	Protein kinase regulators
US10172862B2 (en)	2017-01-30	2019-01-08	Oncoceutics, Inc.	Imipridones for gliomas
GB2596010B (en) *	2019-02-11	2023-03-01	Madera Therapeutics Llc	Use of caseinolytic protease P function as a biomarker of drug response to imipridone-like agents
CA3131740A1 (en)	2019-02-27	2020-09-03	Madera Therapeutics, LLC	Use of caseinolytic protease p function as a biomarker of drug response to imipridone-like agents
EP4192467A1 (en)	2020-08-06	2023-06-14	Eötvös Loránd Tudományegyetem	Synthesis of novel imipridone derivatives and their evaluation for their anticancer activity
CN115448921B (zh) *	2021-06-08	2023-08-01	四川大学	一类咪唑烷并嘧啶酮化合物及在治疗HsClpP介导的疾病中的用途
CN116751199B (zh) *	2023-06-02	2025-03-18	中国科学院基础医学与肿瘤研究所(筹)	一种线粒体蛋白酶靶向嵌合体、制备方法及用途
EP4684834A1 (de) *	2024-07-26	2026-01-28	BRIU GmbH	Kristallformen onkologisch wirksamer imipridone und verfahren zu deren herstellung

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BE786028A (fr) *	1971-07-08	1973-01-08	Boehringer Sohn Ingelheim	2,3-dihydro-oxo-imidazo(1,2-a)-pyrimidines, leurs sels d'addition avec des acides et procedes pour les fabriquer
DE2150062A1 (de)	1971-10-07	1973-04-12	Boehringer Sohn Ingelheim	Imidazo- eckige klammer auf 1,2-a eckige klammer zu -pyrido- eckige klammer auf 4,3-d eckige klammer zu -pyrimidine, deren saeureadditionssalze und verfahren zu deren herstellung
JPS5374893A (en)	1976-12-15	1978-07-03	Fujitsu Ltd	Driving method for semiconductor photosensitive device
JPS6132833U (ja)	1984-07-31	1986-02-27	日信工業株式会社	デイスクブレ−キ装置
EP1517904A4 (en) *	2002-05-23	2007-02-21	Merck & Co Inc	INHIBITORS OF MITOTIC KINESINE
ES2672777T3 (es)	2008-06-09	2018-06-18	Allergan, Inc.	Métodos de tratamiento de estados con mediación alfa-adrenérgica
JP2013525308A (ja)	2010-04-16	2013-06-20	キュリス，インコーポレイテッド	Ｋ−ｒａｓ変異を有する癌の治療
WO2012078448A1 (en) *	2010-12-06	2012-06-14	Schering Corporation	Tricyclic heterocycles useful as dipeptidyl peptidase-iv inhibitors
MX345400B (es) *	2011-03-15	2017-01-30	Chiesi Farm Spa	Derivados de isoxazolidina.
EP2694678A2 (en) *	2011-04-04	2014-02-12	Netherland Cancer Institute	Methods and compositions for predicting resistance to anticancer treatment
EP3679934B1 (en) *	2011-04-29	2024-06-05	The Penn State Research Foundation	Small molecule trail gene induction by normal and tumor cells as an anticancer therapy
WO2015073072A1 (en) *	2013-11-15	2015-05-21	Oncoceutics, Inc.	7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one
US9376437B2 (en)	2013-03-13	2016-06-28	Oncoceutics, Inc	7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy
US9688679B2 (en)	2013-03-13	2017-06-27	Oncoceutics, Inc.	7-benzyl-4-(methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-A]pyrido[3,4-E]pyrimidin-5 (1H)-one, salts thereof and methods of using the same in combination therapy
SI2968294T1 (sl) *	2013-03-13	2019-08-30	Oncoceutics, Inc.	7-benzil-10-(2-metilbenzil)-2,6,7,8,9,10-heksahidroimidazo(1,2-A)pirido (4,3-D)pirimidin-5(3H)-on za uporabo pri zdravljenju raka
US9181237B2 (en) *	2013-10-04	2015-11-10	Mallinckrodt Llc	Substituted berbines and their synthesis
JP6756435B2 (ja)	2014-03-31	2020-09-16	ザスクリプスリサーチインスティテュート	Ｔｒａｉｌ誘導のためのファーマコフォア

2015
- 2015-03-30 JP JP2016559887A patent/JP6756435B2/ja active Active
- 2015-03-30 EP EP15772254.7A patent/EP3125898B1/en active Active
- 2015-03-30 CA CA2944452A patent/CA2944452C/en active Active
- 2015-03-30 HU HUE19218049A patent/HUE069651T2/hu unknown
- 2015-03-30 HR HRP20241680TT patent/HRP20241680T1/hr unknown
- 2015-03-30 SI SI201532040T patent/SI3662910T1/sl unknown
- 2015-03-30 CN CN201580021658.3A patent/CN106456643B/zh active Active
- 2015-03-30 CA CA3158795A patent/CA3158795A1/en active Pending
- 2015-03-30 PT PT157722547T patent/PT3125898T/pt unknown
- 2015-03-30 WO PCT/US2015/023362 patent/WO2015153468A1/en not_active Ceased
- 2015-03-30 SM SM20200219T patent/SMT202000219T1/it unknown
- 2015-03-30 EP EP24192819.1A patent/EP4470617A3/en active Pending
- 2015-03-30 SI SI201531141T patent/SI3125898T1/sl unknown
- 2015-03-30 HR HRP20200478TT patent/HRP20200478T1/hr unknown
- 2015-03-30 DK DK19218049.5T patent/DK3662910T3/da active
- 2015-03-30 PL PL15772254T patent/PL3125898T3/pl unknown
- 2015-03-30 PL PL19218049.5T patent/PL3662910T3/pl unknown
- 2015-03-30 LT LTEP15772254.7T patent/LT3125898T/lt unknown
- 2015-03-30 AU AU2015241069A patent/AU2015241069B2/en active Active
- 2015-03-30 KR KR1020227042050A patent/KR102611067B1/ko active Active
- 2015-03-30 FI FIEP19218049.5T patent/FI3662910T3/fi active
- 2015-03-30 CN CN202010184181.3A patent/CN111499636B/zh active Active
- 2015-03-30 EP EP19218049.5A patent/EP3662910B1/en active Active
- 2015-03-30 US US15/126,192 patent/US10239877B2/en active Active
- 2015-03-30 LT LTEP19218049.5T patent/LT3662910T/lt unknown
- 2015-03-30 RS RS20241340A patent/RS66254B1/sr unknown
- 2015-03-30 ES ES19218049T patent/ES2999685T3/es active Active
- 2015-03-30 RS RS20200336A patent/RS60163B1/sr unknown
- 2015-03-30 PT PT192180495T patent/PT3662910T/pt unknown
- 2015-03-30 ES ES15772254T patent/ES2779979T3/es active Active
- 2015-03-30 KR KR1020167029994A patent/KR102473930B1/ko active Active
- 2015-03-30 HU HUE15772254A patent/HUE049013T2/hu unknown
- 2015-03-30 DK DK15772254.7T patent/DK3125898T3/da active
- 2015-03-30 SM SM20240497T patent/SMT202400497T1/it unknown
2019
- 2019-03-20 US US16/359,633 patent/US10633385B2/en active Active
- 2019-09-10 JP JP2019164086A patent/JP6873201B2/ja active Active
2020
- 2020-03-20 CY CY20201100267T patent/CY1123093T1/el unknown
- 2020-04-14 US US16/848,032 patent/US20200283440A1/en not_active Abandoned
- 2020-12-11 AU AU2020286314A patent/AU2020286314A1/en not_active Abandoned
2021
- 2021-04-20 JP JP2021071035A patent/JP7186256B2/ja active Active
- 2021-07-12 US US17/372,894 patent/US11891392B2/en active Active
2022
- 2022-11-28 JP JP2022188821A patent/JP7688245B2/ja active Active
- 2022-12-08 AU AU2022283729A patent/AU2022283729A1/en not_active Abandoned
2023
- 2023-12-20 US US18/391,420 patent/US20240190877A1/en active Pending
2024
- 2024-07-19 AU AU2024204977A patent/AU2024204977B2/en active Active

Also Published As

Publication number	Publication date
JP7688245B2 (ja)	2025-06-04
KR20220163533A (ko)	2022-12-09
CN106456643B (zh)	2020-04-17
EP3125898A4 (en)	2017-08-16
DK3125898T3 (da)	2020-03-30
US11891392B2 (en)	2024-02-06
SI3125898T1 (sl)	2020-07-31
US20190284188A1 (en)	2019-09-19
AU2015241069B2 (en)	2020-10-15
JP2023022184A (ja)	2023-02-14
DK3662910T3 (en)	2024-11-04
JP6756435B2 (ja)	2020-09-16
RS66254B1 (sr)	2024-12-31
PT3125898T (pt)	2020-04-01
CN106456643A (zh)	2017-02-22
LT3125898T (lt)	2020-04-10
WO2015153468A1 (en)	2015-10-08
CY1123093T1 (el)	2021-10-29
HUE069651T2 (hu)	2025-03-28
KR20160138513A (ko)	2016-12-05
US10239877B2 (en)	2019-03-26
CA3158795A1 (en)	2015-10-08
ES2779979T3 (es)	2020-08-21
ES2999685T3 (en)	2025-02-26
JP2020002170A (ja)	2020-01-09
AU2015241069A1 (en)	2016-10-20
CA2944452A1 (en)	2015-10-08
HUE049013T2 (hu)	2020-08-28
EP3125898B1 (en)	2019-12-25
US20240190877A1 (en)	2024-06-13
SMT202400497T1 (it)	2025-01-14
US20200283440A1 (en)	2020-09-10
CN111499636B (zh)	2023-01-13
EP3125898A1 (en)	2017-02-08
US20220002300A1 (en)	2022-01-06
AU2022283729A1 (en)	2023-02-02
AU2020286314A1 (en)	2021-01-21
KR102473930B1 (ko)	2022-12-05
EP4470617A2 (en)	2024-12-04
US10633385B2 (en)	2020-04-28
HRP20241680T1 (hr)	2025-02-28
SMT202000219T1 (it)	2020-05-08
JP2021119157A (ja)	2021-08-12
JP6873201B2 (ja)	2021-05-19
SI3662910T1 (sl)	2025-05-30
AU2024204977B2 (en)	2026-04-16
JP2017511321A (ja)	2017-04-20
JP7186256B2 (ja)	2022-12-08
KR102611067B1 (ko)	2023-12-06
PL3125898T3 (pl)	2020-11-16
FI3662910T3 (fi)	2024-10-31
PT3662910T (pt)	2024-11-27
AU2024204977A1 (en)	2024-08-08
EP3662910A1 (en)	2020-06-10
EP4470617A3 (en)	2025-02-26
HRP20200478T1 (hr)	2020-07-24
EP3662910B1 (en)	2024-09-18
PL3662910T3 (pl)	2025-08-11
CN111499636A (zh)	2020-08-07
CA2944452C (en)	2022-07-19
US20170107221A1 (en)	2017-04-20
RS60163B1 (sr)	2020-05-29

Publication	Publication Date	Title
LT3662910T (lt)	2024-12-27	Trail geno indukcijai skirtas farmakoforas
DK3102669T3 (da)	2019-08-19	Forbedret bacillevært
DK3233887T3 (da)	2019-05-13	Immunmodulatorer
PL3118311T3 (pl)	2019-09-30	Antysensowny kwas nukleinowy
HUE057846T2 (hu)	2022-06-28	Permanens epigenetikus géncsendesítés
HUE042335T2 (hu)	2019-06-28	ROR-gamma dihidropirrolopiridin inhibitorai
DK3188836T3 (da)	2024-03-11	Dna-syntese
DK3102722T3 (da)	2020-11-16	Genom fraktionering
HUE054784T2 (hu)	2021-09-28	5-klór-2-difluor-metoxifenil-pirazolopirimidin vegyületek, amelyek JAK-gátlók
MA39481A (fr)	2015-09-11	Thérapies ciblées
HUE054514T2 (hu)	2021-09-28	Kemence
HUE042087T2 (hu)	2019-06-28	Inhalátor
DK3186242T3 (da)	2021-12-20	Alfa-amino-beta-carboxymuconsyre-semialdehyd-decarboxylasehæmmere
FR3025617B1 (fr)	2016-12-16	Architecture bi-voies
IL249254A0 (en)	2017-02-28	Gene expression system
EP3125821C0 (en)	2023-06-07	INSERT FOR AN INHALER
IL252086A0 (en)	2017-07-31	Novel methods
IL257500A (en)	2018-04-30	Altered cullin1 gene
LT3628731T (lt)	2021-08-10	Naujas antipresepsino antikūnas
SG11201609108TA (en)	2016-12-29	Antibody gene expression-secretion system
EP2993051A4 (en)	2016-08-03	PRINTER
BR112017008675A2 (pt)	2018-06-19	impressoras
ES1135593Y (es)	2015-04-17	Multibotella
UA28521S (uk)	2014-12-10	Наличка
ES1122680Y (es)	2015-01-27	Ladrillo caravista